Stifel analyst Thomas Shrader laid out three scenarios for Medivation Inc MDVN takeover after the biopharma company rejected Sanofi SA (ADR) SNY's $52.50 acquisition bid.
Shrader raised his target price on the stock by $14 to $66, which is also his minimum takeover price for Medivation.
"Overall, we think the ability of a company to enter the growing arena of metastatic castrate-resistant prostate cancer (mCRPC) with a drug as good as xtandi is relatively unique and we expect any deal to get done at a minimum of about $66 per share with an additional conditional payout for Talazoparib," Shrader wrote in a note.
Shrader, who has a Buy rating on the stock, laid out the following three scenarios that could fetch as much as $85 for Medivation.
Scenario 1:Last week, Goldman Sachs said it expects potential takeout value of Medivation near $70 a share.
AT time of writing, shares of Medivation were down 0.62 percent to $57.44.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.